Korrektion til udsendelse af Halvårsrapport for perioden 1. januar – 30. juni 2026
14.8.2026 11:15:34 CEST | GlobeNewswire by notified | pressemeddelelse
Korrektion til udsendelse af Halvårsrapport for perioden 1. januar – 30. juni 2026
14. august 2026
Meddelelse nr. 10
Tidligere udsendt halvårsrapport havde ikke rapporten vedhæftet, hvorfor meddelelsen genudsendes med rapporten.
Bestyrelsen og direktionen i Pharma Equity Group A/S ("PEG", "Selskabet" eller "Koncernen") har den 14. august 2026 behandlet og godkendt halvårsrapporten for perioden 1. januar – 30. juni 2026 ("H1 2026-rapporten"). Rapporten kan sammenfattes som følger:
Hovedpunkter for perioden:
- Reponex Pharmaceuticals A/S har styrket sin patentposition med et nyt europæisk patent vedrørende behandling af inflammatoriske tarmsygdomme, herunder pouchitis.
- Patentansøgningen vedrørende behandlingsregimet for RNX-051 er gået ind i national fase i en række væsentlige markeder, herunder Europa, USA, Japan, Kina og Indien.
- En voldgiftskendelse har fastslået, at PEG har et gyldigt krav vedrørende tilgodehavendet hos Portinho S.A. Kendelsen styrker det juridiske grundlag for Selskabets fortsatte inddrivelsesarbejde.
- Formuleringen af RNX-051 er færdigudviklet, og produktionen til det planlagte kliniske studie er etableret i Tyskland. Første patient forventes inkluderet ultimo 2026 eller primo 2027, forudsat de resterende regulatoriske, operationelle og finansieringsmæssige forhold.
- Første patient i det planlagte kliniske studie med RNX-011 forventes inkluderet ultimo 2026.
- Dialogen med potentielle licenspartnere fortsætter på tværs af Reponex’ kliniske programmer.
- Reponex undersøger muligheden for at gennemføre kliniske studier i Indien som grundlag for tidligere markedsadgang og markedsspecifikke licensaftaler.
- Reponex fortsætter dialogen om potentielle licensmuligheder i Japan og Abu Dhabi i forbindelse med den videre kliniske udvikling af selskabets programmer, herunder dialog med de japanske myndigheder om RNX-051
- Koncernen har styrket kapitalberedskabet gennem yderligere konvertible instrumenter og lån og arbejder fortsat med yderligere finansiering til understøttelse af de planlagte aktiviteter.
| Key Figures | |||||
| 30-06-2026 | 30-06-2025 | ||||
| TDKK | TDKK | ||||
| Profit/loss | -2.679 | -17.610 | |||
| Receivable Portinho S.A. | 39.332 | 33.697 | |||
| Cash and cash equivalents | 29 | 702 | |||
| Total assets | 44.163 | 37.996 | |||
| Equity | 25.788 | 15.076 | |||
| Convertible instruments | 21.163 | 0 | |||
| Subordinated convertible loans | 4.415 | 15.234 | |||
Udvalgte nøgletal:
- Resultat for H1 2026: DKK -2,7 mio. (H1 2025 (restated): DKK -17,6 mio.)
- Egenkapital pr. 30. juni 2026: DKK 25,8 mio. (30. juni 2025 (restated): DKK 15,1 mio.)
- Likvider pr. 30. juni 2026: DKK 0,029 mio. (30. juni 2025: DKK 0,702 mio.)
Forventninger til 2026
Koncernen fastholder de finansielle forventninger til 2026 som angivet i årsrapporten for 2025 med en forventet omsætning på DKK 3,0–8,6 mio. og negativt EBIT på DKK 5,8–11,4 mio.
Online præsentation
CEO Christian Henrik Tange afholder i dag, den 14. august 2026 kl. 13.00, en online præsentation af halvårsrapporten for H1 2026 samt væsentlige begivenheder i indeværende år.
Tilmelding er gratis og kan ske via linket:
https://www.inderes.dk/videos/pharma-equity-group-praesentation-af-delarsregnskabet-for-h1-2026
Investor Relations
Spørgsmål til rapporten kan rettes til CEO Christian Henrik Tange på e-mail: investor@pharmaequitygroup.com
Yderligere information og tidligere selskabsmeddelelser kan findes på selskabets hjemmeside:
www.pharmaequitygroup.com
Hørsholm, 14. august 2026
Christian Vinding Thomsen, Bestyrelsesformand Christian Henrik Tange, CEO
Om Pharma Equity Group A/S
Pharma Equity Group er et børsnoteret selskab på Nasdaq Copenhagens hovedliste. Selskabets hovedfokus er på at fremme de forskellige lægemiddelkandidater i sit datterselskab, Reponex Pharmaceuticals A/S. Med et urokkeligt fokus på Health Care er Pharma Equity Groups primære mål at tilføre betydelig værdi til Reponex Pharmaceuticals' forskellige lægemiddelkandidater.
Selskabet er forpligtet til at yde omfattende support, ressourcer og ekspertise til at drive udviklingen og succesen af disse lægemiddelkandidater. Som strategisk partner arbejder Pharma Equity Group tæt sammen med Reponex Pharmaceuticals og prioriterer fremme af innovative medicinske løsninger og banebrydende behandlinger. Først når det fulde potentiale i Reponex Pharmaceuticals er blevet udfoldet, er intentionen om at udforske muligheder for at investere i andre virksomheder. Denne tilgang sikrer et stærkt engagement i de aktuelle medicinske projekter og deres udvikling, samtidig med at den – på længere sigt – forbliver åben for nye strategiske investeringer med henblik på fortsat vækst.
Vedhæftede filer
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release
Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a
DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release
Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68
Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release
Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email verdbrefamidlun@landsbankinn.is.
Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release
AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us
Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release
VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin